Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Budigalimab - AbbVie

Next Previous
X
Search
Drug Profile

Budigalimab - AbbVie

Alternative Names: ABBV-181

Latest Information Update: 11 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbbVie
  • Developer AbbVie; Aceragen
  • Class Antineoplastics; Antiretrovirals; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Liver cancer; Non-small cell lung cancer
  • Phase II HIV-1 infections
  • Phase I/II Pancreatic cancer
  • Phase I Small cell lung cancer; Solid tumours; Squamous cell cancer
  • No development reported Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 19 Sep 2024 AbbVie terminates the phase Ib/II trial in Pancreatic cancer(First-line therapy, Combination therapy, Metastatic disease) in the US, Australia, Isreal, South Korea, Puerto Rico and Spain, due to strategic considerations (IV) (NCT04807972)
  • 11 Sep 2024 Phase-I clinical trials in Liver cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in China (IV) (NCT06487559)
  • 05 Jul 2024 AbbVie plans a phase I trial for Liver cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in October 2024 (IV, Infusion) (NCT06487559)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top